Thioridazine Is an Efflux Pump Inhibitor in Mycobacterium avium Complex but of Limited Clinical Relevance.

Antimicrob Agents Chemother 2020 06 23;64(7). Epub 2020 Jun 23.

Radboud Center for Infectious Diseases, Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands

Treatment of complex pulmonary disease (MAC-PD) is challenging partly due to high efflux pump expression. Thioridazine might block these efflux pumps. We explore the efficacy of thioridazine against isolates using MICs, time-kill combination assays, macrophage infection assays, and efflux assays. Thioridazine is bactericidal against , inhibits intracellular growth at 2× MIC, and blocks ethidium bromide efflux. However, its toxicity and low plasma concentrations make it unlikely to add efficacy to MAC-PD therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1128/AAC.00181-20DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318027PMC
June 2020
4.476 Impact Factor

Publication Analysis

Top Keywords

efflux pump
8
assays macrophage
4
combination assays
4
time-kill combination
4
macrophage infection
4
assays efflux
4
assays thioridazine
4
efflux assays
4
mics time-kill
4
infection assays
4
isolates mics
4
efflux pumps
4
block efflux
4
thioridazine block
4
pumps explore
4
explore efficacy
4
thioridazine
4
efficacy thioridazine
4
thioridazine bactericidal
4
bactericidal inhibits
4

Similar Publications